This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
REDWOOD CITY, Calif., Nov. 27, 2013 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel therapeutics that target cancer stem cells (CSCs), or tumor-initiating cells, today announced that Paul J. Hastings, Chairman and Chief Executive Officer of OncoMed, will speak at the 25th Annual Piper Jaffray Healthcare Conference on Tuesday, December 3, 2013 at the New York Palace Hotel in New York City at 10:00 am ET.
To access the live webcast of the talk, please visit the "Events & Presentations" page under the "Investors" tab on OncoMed's website or access the webcast directly at
http://www.media-server.com/m/p/v66aatxw. OncoMed will maintain an archived replay of the webcast on its website for 30 days after the conference.
About OncoMed Pharmaceuticals
OncoMed Pharmaceuticals, Inc., is a clinical-stage company focused on discovering and developing novel therapeutics targeting cancer stem cells (CSCs). OncoMed has five anti-cancer product candidates in clinical development, including demcizumab (OMP-21M18, Anti-DLL4), OMP-59R5 (Anti-Notch2/3), OMP-52M51 (Anti-Notch1), vantictumab (OMP-18R5, Anti-Fzd7), and OMP-54F28 (Fzd8-Fc), which target key CSC signaling pathways including Notch and Wnt. OncoMed has two other antibodies in preclinical development with Investigational New Drug filings planned as early as 2014. OncoMed is also pursuing discovery of additional novel anti-CSC product candidates. OncoMed has formed strategic alliances with Bayer Pharma AG and GlaxoSmithKline (GSK). Additional information can be found at the company's website:
CONTACT: Investor Contact:
Karen L. Bergman or
(650) 575-1509 or (415) 794-8662